IMPAX LABORATORIES INC's ticker is IPXL and the CUSIP is 45256B101. A total of 180 filers reported holding IMPAX LABORATORIES INC in Q1 2014. The put-call ratio across all filers is 0.75 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2017 | $130,000 | -9.7% | 10,245 | -5.4% | 0.00% | 0.0% |
| Q4 2016 | $144,000 | -41.9% | 10,835 | +3.3% | 0.00% | -50.0% |
| Q3 2016 | $248,000 | +2.5% | 10,485 | +85.5% | 0.00% | 0.0% |
| Q4 2015 | $242,000 | +7.1% | 5,652 | -11.9% | 0.00% | 0.0% |
| Q3 2015 | $226,000 | -51.3% | 6,412 | -36.5% | 0.00% | -50.0% |
| Q2 2015 | $464,000 | -40.8% | 10,100 | -39.6% | 0.00% | -42.9% |
| Q1 2015 | $784,000 | +48.5% | 16,730 | +0.4% | 0.01% | +40.0% |
| Q4 2014 | $528,000 | +28.8% | 16,670 | -3.6% | 0.01% | 0.0% |
| Q3 2014 | $410,000 | -22.5% | 17,295 | -1.9% | 0.01% | 0.0% |
| Q2 2014 | $529,000 | -21.9% | 17,635 | -31.2% | 0.01% | -28.6% |
| Q1 2014 | $677,000 | +122.0% | 25,630 | +110.9% | 0.01% | +133.3% |
| Q4 2013 | $305,000 | +22.5% | 12,150 | 0.0% | 0.00% | 0.0% |
| Q3 2013 | $249,000 | -15.0% | 12,150 | -17.2% | 0.00% | -25.0% |
| Q2 2013 | $293,000 | – | 14,680 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aravt Global | 2,670,000 | $125,143,000 | 9.40% |
| Krensavage Asset Management, LLC | 410,944 | $19,261,000 | 8.77% |
| BANBURY PARTNERS LLC | 292,660 | $13,717,000 | 8.70% |
| Slate Path Capital LP | 1,935,000 | $90,693,000 | 5.72% |
| BLUE JAY CAPITAL MANAGEMENT, LLC | 285,000 | $13,358,000 | 4.69% |
| Orbimed Advisors | 6,678,000 | $312,998,000 | 2.67% |
| Pennant Capital Management, LLC | 2,025,000 | $94,912,000 | 1.78% |
| Iguana Healthcare Management, LLC | 75,000 | $3,515,000 | 1.48% |
| Leonard Capital Management, Inc. | 89,235 | $4,182,000 | 1.44% |
| HUSSMAN STRATEGIC ADVISORS, INC. | 250,000 | $11,718,000 | 1.23% |